Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 203 participants.

Also called NCT02664155

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 203 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02664155
  • EudraCT 2016-000858-35
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02664155. Randomized; no masking; primary purpose treatment. Start 2016-10-19 (actual); primary completion 2021-11-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
Acronym
VERDICT
Condition
Renal Insufficiency
Intervention (Drug)
Apixaban
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Heparin
Intervention (Drug)
VKA
Lead sponsor
Centre Hospitalier Universitaire de Saint Etienne (class: other)
Collaborator
Ministry of Health, France (class: other government)

Record details

Record id
cardio:ct-nct02664155
Content hash
d11f615d5a4cc6811b9624616ad297817df6c269a2cd5405a8fa880ed18b61cc